Medline (NASDAQ:MDLN) Insider Purchases $170,750.00 in Stock

Medline (NASDAQ:MDLN - Get Free Report) insider Jessi Corcoran acquired 5,000 shares of the business's stock in a transaction dated Friday, June 5th. The shares were acquired at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider directly owned 5,000 shares in the company, valued at $170,750. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Medline Trading Up 6.5%

• A Fresh IPO That Long-Term Investors Shouldn’t Ignore

NASDAQ:MDLN opened at $36.01 on Wednesday. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The company's 50-day simple moving average is $41.18.

Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion for the quarter. The company's revenue was up 10.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Medline will post 1.51 EPS for the current year.

Analyst Ratings Changes

---

---

MDLN has been the topic of several recent analyst reports. BMO Capital Markets lifted their price objective on Medline from $45.00 to $54.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Leerink Partners set a $56.00 price objective on Medline in a report on Wednesday, February 25th. Morgan Stanley lifted their price objective on Medline from $48.00 to $52.00 and gave the company an "overweight" rating in a report on Monday, March 2nd. JPMorgan Chase & Co. lifted their target price on Medline from $50.00 to $53.00 and gave the company an "overweight" rating in a research report on Tuesday, March 10th. Finally, Royal Bank Of Canada lifted their target price on Medline from $47.00 to $53.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $50.54.

View Our Latest Research Report on Medline

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Sound Income Strategies LLC acquired a new position in shares of Medline during the 4th quarter worth approximately $25,000. Entrust Financial LLC acquired a new position in shares of Medline during the 4th quarter worth approximately $26,000. NBC Securities Inc. acquired a new position in shares of Medline during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC acquired a new position in shares of Medline during the 1st quarter worth approximately $30,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Medline during the 4th quarter worth approximately $31,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline completed a major debt refinancing, including new senior secured notes and a new term loan facility, which should reduce near-term funding uncertainty and support liquidity. Medline shares rise as investors digest recent refinancing and large secondary offering
• Positive Sentiment: Investors may also be responding favorably to the fact that the large 72.6 million-share secondary offering was sold by existing shareholders, meaning it was not a primary dilution event for the company itself. Medline shares rise as investors digest recent refinancing and large secondary offering
• Positive Sentiment: Recent insider buying, including a purchase by Principal Accounting Officer Jessi L. Corcoran, may be helping sentiment by signaling internal confidence. MarketBeat MDLN news
• Neutral Sentiment: Medline presented at the Goldman Sachs 47th Annual Global Healthcare Conference, which may have helped keep attention on the company but did not include a clear new catalyst in the provided details. Medline conference transcript
• Neutral Sentiment: Medline is also expanding its manufacturing footprint in Slovakia, a longer-term growth initiative that is supportive but not an immediate stock-moving event. Medline expands manufacturing footprint in Slovakia
• Negative Sentiment: Ongoing securities-fraud investigation headlines could weigh on shares by raising legal and disclosure-risk concerns, even if no wrongdoing has been proven. Securities fraud investigation announced
• Negative Sentiment: Analyst commentary has turned a bit more cautious, with Barclays recently trimming its price target to $45 from $50 due to margin-pressure concerns. Medline analyst coverage article

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

Featured Articles

• Five stocks we like better than Medline
• The Bank of Mom and Dad Is Booming—3 Stocks to Watch
• Corning Is Paving AI's Future With Glass
• Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
• Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].